Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
17
Recruiting, any sponsor type, condition "Clostridioides difficile"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed135
17 trials
Showing 1 to 17, recently updated first.
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT07649096 · 56 participants (planned) · Start Nov 12, 2026 · Primary completion Aug 22, 2028
Drug: FZ002 · For: Clostridium Difficile Infection
Sites: Knoxville, Tennessee
- Vancomycin Taper to Prevent Recurrent Clostridioides DifficilePivotal-lookingRecruiting
McGill University Health Centre/Research Institute of the McGill University Health CentreAcademic, hospital or other
NCT07328971 · 500 participants (planned) · Start May 1, 2026 · Primary completion Jul 1, 2031
Drug: Fidaxomicin; Vancomycin capsule · For: Clostridia Difficile Colitis
Sites: Edmonton, Canada; Montreal, Canada
- ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile InfectionRecruiting
Acurx Pharmaceuticals Inc.Industry
NCT07513285 · 20 participants (planned) · Start Sep 25, 2026 · Primary completion Sep 29, 2027
Drug: Ibezapolstat · For: Clostridium Difficile Infection Recurrence
Sites: Sacramento, California; Hamden, Connecticut; Coral Gables, Florida · 19 sites in all
- VE303 for Prevention of Recurrent Clostridioides Difficile InfectionPivotal-lookingRecruiting
Vedanta Biosciences, Inc.Industry
NCT06237452 · 852 participants (planned) · Start May 20, 2024 · Primary completion Jun 2027
Drug: VE303; Placebo · For: Clostridium Difficile; Clostridium Difficile Infections; Clostridium Difficile Infection Recurrence and 7 more
Sites: Huntsville, Alabama; Chandler, Arizona; Phoenix, Arizona · 215 sites in all
- Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal AntibodyPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07285213 · 230 participants (planned) · Start Dec 10, 2025 · Primary completion Apr 20, 2027
Drug: AZD5148 · For: Clostridioides Difficile Infection
Sites: Phoenix, Arizona; Chula Vista, California; Sacramento, California · 117 sites in all
- A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and OlderPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07282665 · 32,500 participants (planned) · Start Dec 10, 2025 · Primary completion Dec 11, 2028
Drug: C.difficile vaccine · For: Clostridoides Difficile Associated Disease
Sites: Athens, Alabama; Guntersville, Alabama; Huntsville, Alabama · 185 sites in all
Medical College of WisconsinAcademic, hospital or other
NCT06884748 · 30 participants (planned) · Start Jun 30, 2026 · Primary completion May 1, 2028
Drug: Ursodiol 500 MG · For: Clostridioides Difficile Infection
Sites: Milwaukee, Wisconsin
Hospices Civils de LyonAcademic, hospital or other
NCT06306014 · 56 participants (planned) · Start May 7, 2024 · Primary completion Jan 7, 2028
Drug: EXL01; EXL01 and 1 more · For: Clostridioides Difficile Infection; Recurrent Infection
Sites: Annecy, France; Clermont-Ferrand, France; Grenoble, France · 10 sites in all
University of MinnesotaAcademic, hospital or other
NCT06370884 · 40 participants (planned) · Start Feb 1, 2024 · Primary completion Dec 1, 2027
Drug: IMT · For: Recurrent Clostridioides Difficile Infection; Colonic Surgery
Sites: Minneapolis, Minnesota
Duke UniversityAcademic, hospital or other
NCT02127398 · 77 participants (planned) · Start Apr 2016 · Primary completion May 2027
Drug: fecal microbiota · For: Clostridium Difficile Colitis
Sites: Durham, North Carolina
- Fecal Microbiota Transplantation in Clostridioides Difficile Infection First Episode and First RecurrencePivotal-lookingRecruiting
Benoit GueryAcademic, hospital or other
NCT05266807 · 100 participants (planned) · Start Mar 15, 2023 · Primary completion Apr 1, 2027
Drug: oral capsulized Fecal Microbiota Transplantation; Vancomycin or Fidaxomicin · For: Clostridioides Difficile Infection
Sites: Basel, Switzerland; Bern, Switzerland; Fribourg, Switzerland · 8 sites in all
- Secondary Prevention of Clostridioides Difficile Using VancomycinPivotal-lookingRecruiting
McGill University Health Centre/Research Institute of the McGill University Health CentreAcademic, hospital or other
NCT06979609 · 300 participants (planned) · Start Nov 1, 2025 · Primary completion Oct 1, 2028
Drug: Oral Vancomycin Prophylaxis; Placebo · For: Clostridioides Difficile Infection; Clostridioides Difficile Infection Recurrence; Clostridoides Difficile Associated Disease
Sites: Montreal, Canada
- FMT Capsules for rCDIPivotal-lookingRecruiting
Helsinki University Central HospitalAcademic, hospital or other
NCT07458984 · 76 participants (planned) · Start Apr 25, 2026 · Primary completion Dec 31, 2029
Drug: Healthy donor stool; placebo capsule · For: Clostridioides Difficile Infection Recurrence; FMT
Sites: Helsinki, Finland
Fondazione Policlinico Universitario Agostino Gemelli IRCCSAcademic, hospital or other
NCT06071312 · 64 participants (planned) · Start Sep 23, 2023 · Primary completion Sep 24, 2026
Drug: single FMT; sequential FMT · For: Clostridium Difficile; Ulcerative Colitis
Sites: Rome, Italy
- Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill PatientsPivotal-lookingRecruiting
Riverside University Health System Medical CenterAcademic, hospital or other
NCT07221370 · 176 participants (planned) · Start Oct 21, 2024 · Primary completion Dec 31, 2026
Drug: Vancomycin 125mg; Placebo · For: Clostridium Difficile Infection; Vancomycin Resistant Enterococci Infection
Sites: Moreno Valley, California
Englewood Hospital and Medical CenterAcademic, hospital or other
NCT01905709 · 100 participants (planned) · Start Jul 2013 · Primary completion Jul 2026
Drug: Human fecal matter · For: Clostridium Difficile Infection
Sites: Englewood, New Jersey
- Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)Pivotal-lookingRecruiting
University of VirginiaAcademic, hospital or other
NCT04305769 · 260 participants (planned) · Start Jun 1, 2021 · Primary completion Dec 31, 2026
Drug: Alanyl-glutamine · For: Clostridioides Difficile Infection; Clostridium Difficile Infection; Clostridium Difficile Diarrhea and 1 more
Sites: Charlottesville, Virginia; Roanoke, Virginia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.